Summit Therapeutics

http://www.summitplc.com/

Last activity: 02.10.2026

Active - Reference to Summit Therapeutics

Categories: ChemicalDevelopmentDrugMedtech

We are a clinical-stage drug discovery and development company advancing innovative therapies to significantly advance the current standard of treatment for serious unmet medical needs.

Twitter LinkedIn Email

Mentions

Overview

Location

United States, Massachusetts, Cambridge

Investors 1

Date	Name	Website
Sign up to see	Sign up to see	Sign up to see

Mentions in press and media 26

Date	Title	Description
Sign up to see	Sign up to see	Sign up to see
Jul 31, 2025	Pandemic darlings Moderna, BioNTech are now on two different paths	Covid-19 vaccine makers Moderna and BioNTech became household names almost overnight. Moderna and BioNTech have spent their Covid vaccine windfalls differently, with Moderna investing in its own mRNA technology and BioNTech pursuing deals t...
Apr 26, 2025	The Vaccine Tug-of-War: Novavax's Path to Approval Amidst Political Storms	In the world of vaccines, the stakes are high. Novavax, a player in the COVID-19 vaccine arena, is navigating a turbulent sea. The company recently announced that its COVID-19 shot is on track for full approval from the FDA. But the journey...
Apr 26, 2025	Ivonescimab Receives NMPA Approval for First-Line Treatment of PD-L1-Positive NSCLC, Based on Breakthrough Head to Head Phase III Trial Demonstrating Superior Efficacy Over Pembrolizumab	HONG KONG, April 26, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that its globally first-in-class PD-1/VEGF bispecific antibody, ivonescimab, has received approval from th...
Mar 31, 2025	Akeso's 2024 Results: Strengthening Global Competitiveness and Transforming the Treatment Landscape with Bispecific Antibodies	Key Highlights: Global first "immuno + anti-vascular" bispecific antibody approved: ivonescimab for EGFR-TKI resistant nsq-NSCLC. Phase III HARMONi study topline data expected mid-2025 (FDA FTD). ivonescimab outperforms pembrolizu...
Mar 1, 2025	The New Frontier of Cancer Treatment: Akeso and Summit Therapeutics Join Forces with Pfizer	In the relentless battle against cancer, innovation is the lifeblood that fuels hope. Akeso, Inc., a biopharmaceutical trailblazer, has announced a significant collaboration with Summit Therapeutics and Pfizer. This partnership aims to expl...
Mar 1, 2025	The Future of Cancer Treatment: A New Dawn with Ivonescimab and ADCs	In the ever-evolving landscape of cancer treatment, innovation is the lifeblood that fuels hope. Akeso, Inc. has stepped into the spotlight with its groundbreaking collaboration with Summit Therapeutics and Pfizer. This partnership aims to ...
Feb 25, 2025	Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs	HONG KONG, Feb. 25, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a clinical trial collabo...
Feb 21, 2025	Akeso Enrolled First Patient in The Phase III Clinical Trial of Ivonescimab in Combination with Chemotherapy for First-Line Treatment of Triple-Negative Breast Cancer	HONG KONG, Feb. 21, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced the company has successfully enrolled the first patient in its multicenter, randomized, double-blind Phase III cli...
Feb 6, 2025	Akeso Announces the Completion of Patient Enrollment in the Phase III Clinical Trial (HARMONi-6) Comparing Ivonescimab and Tislelizumab for First-Line Treatment of Sq-NSCLC	HONG KONG, Feb. 6, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce the completion of patient enrollment in the global Phase III clinical trial (HARMONi-6/AK112-306) evaluating...
Jan 23, 2025	The Rise of Innovative Cancer Therapies: A New Era in Oncology	The landscape of cancer treatment is evolving. New players are entering the field, armed with innovative therapies that promise to change the game. Two recent developments from Lepu Biopharma and Akeso Inc. highlight this shift. Both compan...
Jan 22, 2025	Akeso Received Payment for the Development Collaboration on Tagitanlimab	HONG KONG, Jan. 22, 2025 /PRNewswire/ -- On January 22, 2025, Akeso Inc. (9926.HK) announced that it had received payment from Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. ("Sichuan Kelun") for their collaboration on ...
Nov 9, 2024	The 10X Wealth Conference: A Gateway to Financial Mastery	In the heart of Aventura, Florida, a financial revolution is brewing. The 10X Wealth Conference, hosted by the renowned Grant Cardone, is set to unfold on November 17-18, 2024. This two-day event promises to be a treasure trove of knowledge...
Nov 7, 2024	10X Wealth Conference, Hosted by Grant Cardone, Announces Impressive and Unparalleled Speaker Line Up	10X Wealth Conference Featuring globally recognized financially enterprising guest speakers: Mayor of Miami, Francis Suarez; Fox Business' Charlie Gasparino; Najarian Brothers; Gary Cohn, Vice Chair of IBM; David Weild, Former Vice Chairman...
Nov 1, 2024	Akeso Biopharma: Pioneering New Frontiers in Cancer Treatment	In the realm of cancer treatment, hope often flickers like a candle in the dark. Akeso Biopharma, a rising star in the biopharmaceutical industry, is working to turn that flicker into a blazing light. With recent announcements of groundbrea...
Nov 1, 2024	Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combination as First-Line Therapy for Biliary Tract Tumors, Compared to Durvalumab	HONG KONG, Nov. 1, 2024 /PRNewswire/ -- Akeso Biopharma (9926.HK) is pleased to announce the successful enrollment of the first patient in the HARMONi-GI-01/AK112-309 study, a randomized, controlled, multicenter Phase III registration study...
Oct 31, 2024	Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combined with Ligufalimab (CD47) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma (HNSCC), Compared to Pembrolizumab	HONG KONG, Oct. 31, 2024 /PRNewswire/ -- Akeso Biopharma (9926.HK) is pleased to announce the enrollment of the first patient in its randomized, controlled, multicenter Phase III clinical study (AK117-302) for head and neck squamous cell ca...
Sep 26, 2024	A Surfer Without a Degree Is Worth $16 Billion After His Biotech Company's Stock Soared 1,100% in a Year He took classes at UC Santa Barbara in the 1960s but didn't get a degree. Instead, he was focused on finding ways to make money.	This article originally appeared on Business Insider. A surfer without a college degree has gone from baking cookies to building robots, minting billions in biotech, and ranking among the world's richest people. Bob Duggan, 80, is the co-C...
Sep 12, 2024	A New Dawn in Lung Cancer Treatment: Ivonescimab's Promising Phase II Results	In the ever-evolving landscape of cancer treatment, a new player has emerged. Ivonescimab, a bispecific antibody targeting PD-1 and VEGF, is making waves in the fight against non-small cell lung cancer (NSCLC). Recently presented at the 25t...
Sep 9, 2024	Perioperative Ivonescimab (PD-1/VEGF) for NSCLC Demonstrated Clinically Significant Phase II Results, Presented in Oral Session at WCLC 2024	HONG KONG, Sept. 9, 2024 /PRNewswire/ -- Akeso (9926. HK) announced that its internally developed PD-1/VEGF bispecific antibody ivonescimab showed clinically significant results from a Phase II study, either as a monotherapy or in combinati...
Sep 8, 2024	Perioperative Ivonescimab (PD-1/VEGF) for NSCLC Demonstrated Clinically Significant Phase II Results, Presented in Oral Session at WCLC 2024	HONG KONG, Sept. 8, 2024 /PRNewswire/ -- Akeso (9926. HK) announced that its internally developed PD-1/VEGF bispecific antibody ivonescimab showed clinically significant results from a Phase II study, either as a monotherapy or in combinati...
Aug 15, 2024	Ivonescimab (PD-1/VEGF) Received Priority Review from China's NMPA for First-Line Treatment of PD-L1 Positive NSCLC	The Second Indication of Ivonescimab in NSCLC 2L+ EGFRm NSCLC Already Approved in May 2024 HONG KONG, Aug. 15, 2024 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) ("Akeso,") today announced that the National Center for Drug Evaluatio...
Jun 1, 2024	Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy	Separate & Distinct from HARMONi-2 Announcement, HARMONi-A Showed Clinically Meaningful and Statistically Significant Benefit: PFS Hazard Ratio of 0.46 For Subset of Patients Previously Receiving 3rd Generation EGFR-TKI: PFS Hazard Rati...
Oct 5, 2020	With Covid-19 mucking the tires, Robert Duggan throws another $50M behind his big antibiotics play	Robert Duggan is upping his ante on Summit Therapeutics. The billionaire investor quietly bid up to 65% of the small antibiotic developer before making himself CEO earlier this year and legally moving the company f...
Jun 18, 2019	Unity's early longevity data look 'encouraging'; Adaptive Biotechnologies looks to raise $200M in IPO	→ Bob Nelsen-backed longevity startup Unity $UBX on Tuesday unveiled the first ever in-human data on its drug, UBX0101, which is designed to delay the aging process by snuffing senescent (old) cells. The first part (A) of the sm...
Jun 29, 2016	The biotech IPO feast flags as investors lose their appetite for R&D risk	There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund...

Reviews 0

FAQ about Summit Therapeutics

What has the press written about Summit Therapeutics?

Parsers VC has collected 26 articles mentioning Summit Therapeutics, among them “Pandemic darlings Moderna, BioNTech are now on two different paths” (Jul 31, 2025) and “The Vaccine Tug-of-War: Novavax's Path to Approval Amidst Political Storms” (Apr 26, 2025).

Is Summit Therapeutics still active?

Yes, Summit Therapeutics is active; its latest activity on Parsers VC dates from Oct 2, 2026.